Quick Answer
Vistagen Therapeutics, Inc. reported Research And Development Expense of $39.38 million for the year ending 2025.
- Vistagen Therapeutics, Inc. showed an increase of +96.7% in Research And Development Expense from 2024 to 2025.
- This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2011 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2011 to 2025), Vistagen Therapeutics, Inc.'s Research And Development Expense has grown by 970.5%.
- Historical annual values: Fiscal year 2025: $39.38 million | Fiscal year 2024: $20.02 million | Fiscal year 2023: $44.38 million | Fiscal year 2022: $35.41 million | Fiscal year 2021: $11.93 million | Fiscal year 2020: $13.37 million | Fiscal year 2019: $17.10 million | Fiscal year 2018: $7.76 million | Fiscal year 2017: $5.20 million | Fiscal year 2016: $3.93 million | Fiscal year 2015: $2.43 million | Fiscal year 2013: $3.43 million | Fiscal year 2012: $5.39 million | Fiscal year 2011: $3.68 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: